Bath & Body Works (NYSE:BBWI – Get Free Report) had its price objective dropped by stock analysts at UBS Group from $22.00 to $19.00 in a report issued on Friday, Benzinga reports. The firm presently has a “neutral” rating on the stock. UBS Group‘s price target suggests a potential upside of 0.85% from the stock’s previous close.
BBWI has been the topic of several other research reports. Citigroup upgraded Bath & Body Works from a “neutral” rating to a “buy” rating and set a $25.00 price objective on the stock in a report on Tuesday, August 18th. Deutsche Bank set a $22.00 target price on Bath & Body Works in a report on Thursday, August 27th. Argus reaffirmed a “hold” rating on shares of Bath & Body Works in a research report on Wednesday, September 16th. Jefferies Financial Group reiterated a “hold” rating and set a $21.00 price target on shares of Bath & Body Works in a research note on Thursday. Finally, BMO Capital Markets reduced their price target on shares of Bath & Body Works from $24.00 to $20.00 and set a “market perform” rating on the stock in a research report on Friday. Four research analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $22.00.
Read Our Latest Analysis on BBWI
Bath & Body Works Trading Down 0.4%
Bath & Body Works stock traded down $0.07 during trading on Friday, hitting $18.84. The company had a trading volume of 2,901,793 shares, compared to its average volume of 6,029,677. The stock has a market cap of $3.80 billion, a price-to-earnings ratio of 4.91, a price-to-earnings-growth ratio of 0.93 and a beta of 1.31. Bath & Body Works has a 1-year low of $14.27 and a 1-year high of $24.94. The company’s 50 day simple moving average is $19.24 and its 200-day simple moving average is $19.77.
Bath & Body Works (NYSE:BBWI – Get Free Report) last released its quarterly earnings results on Thursday, November 19th. The company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.14. Bath & Body Works had a negative return on equity of 53.48% and a net margin of 10.83%. The company had revenue of $1.58 billion for the quarter, compared to analysts’ expectations of $1.55 billion. During the same period in the prior year, the firm earned $0.37 earnings per share. The firm’s revenue was down 1.1% compared to the same quarter last year. Bath & Body Works has set its Q4 2026 guidance at 1.410-1.610 EPS and its FY 2026 guidance at 2.600-2.800 EPS. As a group, analysts forecast that Bath & Body Works will post 2.74 earnings per share for the current fiscal year.
Institutional Trading of Bath & Body Works
A number of large investors have recently made changes to their positions in the company. Elevation Wealth Partners LLC raised its holdings in Bath & Body Works by 5,278.8% in the second quarter. Elevation Wealth Partners LLC now owns 1,775 shares of the company’s stock valued at $41,000 after acquiring an additional 1,742 shares in the last quarter. Parallel Advisors LLC lifted its stake in Bath & Body Works by 35.5% in the first quarter. Parallel Advisors LLC now owns 2,570 shares of the company’s stock worth $48,000 after acquiring an additional 673 shares during the last quarter. Meeder Asset Management Inc. acquired a new position in Bath & Body Works during the 2nd quarter worth approximately $66,000. Global Retirement Partners LLC acquired a new position in Bath & Body Works during the 2nd quarter worth approximately $71,000. Finally, United Southern Bank Trust Department acquired a new position in Bath & Body Works during the 3rd quarter worth approximately $58,000. 95.14% of the stock is currently owned by hedge funds and other institutional investors.
Trending Headlines about Bath & Body Works
Investors following BBWI have been watching these headlines:
- Neutral Sentiment: The company launched a limited-edition holiday fragrance collection with Pantone, featuring candles and hand soaps. The collaboration could support seasonal product interest, though its financial impact is unclear. Pantone collection announcement
- Negative Sentiment: Fourth-quarter EPS guidance of $1.41–$1.61 fell short of analysts’ $1.72 estimate, and reports pointed to softer holiday sales. Although the company raised its full-year sales outlook, its adjusted EPS guidance was maintained, and Q3 revenue remained down year over year. Outlook report
- Negative Sentiment: Several firms lowered their price targets, including JPMorgan ($24 to $23), BMO Capital Markets ($24 to $20), Morgan Stanley ($22 to $21), Robert W. Baird ($23 to $22), and Wells Fargo ($25 to $24). Most maintained neutral or market-perform ratings, while Wells Fargo remained overweight. BMO Capital Markets ratings
About Bath & Body Works
Bath & Body Works, Inc. is a specialty retailer focused on personal care and home fragrance products. Its offerings include body lotions, soaps, fragrances, hand sanitizers, candles and other home-fragrance items, sold under the Bath & Body Works and White Barn brands. The company serves customers through its stores and e-commerce platform in the United States and Canada, as well as through international franchise, license and wholesale partners. Bath & Body Works traces its roots to a store launched in 1990.
Featured Articles
- Five stocks we like better than Bath & Body Works
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
- Cracks in the Crockery? Williams-Sonoma Insiders Sell Shares
Receive News & Ratings for Bath & Body Works Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bath & Body Works and related companies with MarketBeat.com's FREE daily email newsletter.
